(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.36%.
Quoin Pharmaceuticals's earnings in 2026 is -$16,990,211.On average, 6 Wall Street analysts forecast QNRX's earnings for 2026 to be -$455,656,724, with the lowest QNRX earnings forecast at -$544,909,797, and the highest QNRX earnings forecast at -$315,904,000. On average, 5 Wall Street analysts forecast QNRX's earnings for 2027 to be -$205,780,456, with the lowest QNRX earnings forecast at -$268,666,019, and the highest QNRX earnings forecast at -$141,713,944.
In 2028, QNRX is forecast to generate -$143,042,512 in earnings, with the lowest earnings forecast at -$154,310,739 and the highest earnings forecast at -$129,166,355.